Ultomiris is reimbursed for aHUS in Korea
By Son, Hyung Min | translator Alice Kang
25.01.16 05:00:55
가나다라
0
Will be reimbursed for thrombotic microangiopathy with renal impairment aHUS starting this month
Demonstrated efficacy in both adult and pediatric patients...sustained terminal complement inhibition
▲Dr. Jinseok Kim, professor of hematology at Severance Hospital.
Ultomiris has been reimbursed in Korea for atypical hemolytic uremic syndrome (aHUS) since January. While experts have welcomed the news of its reimbursement, they have also raised the need for systematic improvements to the stringent conditions for reimbursement, including the preliminary review requirement.On the 10th, AstraZeneca Korea held a press conference at JW Marriott Dongdaemun Square Seoul to celebrate the reimbursement coverage of Ultomiris for aHUS in Korea.
Starting this month, Ultomiris will be reimbursed by health insurance for patients with aHUS with thrombotic microangiopathy (TMA) and kidney damage. This is expected to improve access to treatment for patients with aH
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)